News After phase 3 hit, Spine seeks path forward for pain drug The first phase 3 readout with Spine BioPharma's drug candidate for chronic low back pain has proved disappointing.
News Amgen's Imdelltra scores again in small cell lung cancer Amgen's Imdelltra and AstraZeneca's Imfinzi have improved survival compared to Imfinzi alone as first-line maintenance treatment for ES-SCLC.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
